1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Amgen’s Bufferless Eylea Biosimilar Again Knocks Back Regeneron’s Injunctive Bid

‘A Substantial Question Of Noninfringement,’ US Federal Circuit Finds As It Affirms On Appeal

 
• By Dean Rudge

Amgen’s biosimilar aflibercept formulation is keeping it head and shoulders above other would-be Eylea biosimilar competitors, while continuing to frustrate originator Regeneron’s push to block sales of the product while it battles Amgen over alleged infringement of a key US patent.

(Shutterstock)

Amgen’s biosimilar to Regeneron’s Eylea (aflibercept) will remain available on the US market while the two companies continue to litigate over a key patent, after the US Court of Appeals for the Federal Circuit affirmed an order denying the originator’s bid for a preliminary injunction.

The Federal Circuit in a 14 March judgment noted that Amgen’s Pavblu (aflibercept-ayyh) formulation, “while contain[ing] a version of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Legal & IP

US Court Agrees To Throw Out Viatris Wegovy Infringement Case

 
• By Dean Rudge

Viatris’ Mylan has won a key patent case against Novo Nordisk over generic Wegovy, with a US federal district judge ruling Mylan’s label did not encourage use that infringed Novo’s method-of-treatment patent.

Sun Strikes Further US Price-Fixing Settlement For $200m

 
• By Dave Wallace

The latest development in the long-running US generic price-fixing saga has seen Sun Pharma agree a $200m settlement in connection with an end purchaser action in Pennsylvania.

UK Xtandi Patent Stands Strong As Accord, Sandoz, Teva Lose Appeal

 
• By Dean Rudge

The Court of Appeal in London has upheld a key UK patent shielding Astellas’ Xtandi, rejecting claims by a trio of generic drugmakers that it was obvious after finding that the generics firms’ expert analysis was tainted by hindsight.